These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma. Sato Y; Nakano K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S Anticancer Res; 2021 Jan; 41(1):527-532. PubMed ID: 33419852 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas. López-Álvarez M; González-Aguilera C; Moura DS; Sánchez-Bustos P; Mondaza-Hernández JL; Martín-Ruiz M; Renshaw M; Ramos R; Castilla C; Blanco-Alcaina E; Hindi N; Martín-Broto J Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614121 [TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates. Haddox CL; Nathenson MJ; Mazzola E; Lin JR; Baginska J; Nau A; Weirather JL; Choy E; Marino-Enriquez A; Morgan JA; Cote GM; Merriam P; Wagner AJ; Sorger PK; Santagata S; George S Clin Cancer Res; 2024 Apr; 30(7):1281-1292. PubMed ID: 38236580 [TBL] [Abstract][Full Text] [Related]
16. A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin. Inagaki C; Shimoi T; Okuma H; Kitano A; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Yoshida A; Fujiwara Y; Tamura K Anticancer Drugs; 2018 Jan; 29(1):97-101. PubMed ID: 29176397 [TBL] [Abstract][Full Text] [Related]
17. Eribulin Shows Promise in Advanced Sarcoma. Cancer Discov; 2015 Jul; 5(7):OF4. PubMed ID: 26045011 [No Abstract] [Full Text] [Related]
18. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682 [TBL] [Abstract][Full Text] [Related]
19. Complete Response to Eribulin in a Patient with Unresectable Liposarcoma: A Case Report and Implications of New Biomarkers. Nakamura H; Takada K; Emori M; Hayasaka N; Sugita S Intern Med; 2022 Dec; 61(23):3617-3621. PubMed ID: 35527027 [TBL] [Abstract][Full Text] [Related]
20. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. Demetri GD; Schöffski P; Grignani G; Blay JY; Maki RG; Van Tine BA; Alcindor T; Jones RL; D'Adamo DR; Guo M; Chawla S J Clin Oncol; 2017 Oct; 35(30):3433-3439. PubMed ID: 28854066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]